Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNF139 divergent transcript (RNF139-DT), also known as RNF139-AS1 or RNF139 antisense RNA 1 (head to head), is a long non-coding RNA gene. It is classified as part of the lncRNA family and does not encode a protein. Associations reported include glioma susceptibility 1, but there is no established therapeutic relevance, known molecular function, or interaction with drugs reported in major databases[4][1][5][6]. The transcript is not listed as a part of any known Mendelian disease phenotype and its precise biological function remains uncharacterized[5][6].\n\nClarification: This target is a non-coding RNA and is not a receptor, enzyme, transporter, or other traditional drug target. There are no known interacting drugs, biomarkers, mechanisms of action, or established disease roles beyond genetic association studies[4][5][6]. There are no major issues with the spelling or identification of this target, but its biological and therapeutic roles are incompletely characterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNF139 divergent transcript (RNF139-DT).